|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.|
|Rapid review commissioned||03/05/2017|
|Rapid review completed||30/05/2017|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.|
The HSE has approved reimbursement following confidential price negotiations May 2018.